The role of SGLT2 inhibitors in managing type 2 diabetes.

JAAPA : Official Journal of the American Academy of Physician Assistants
Velen Tat, Christopher P Forest

Abstract

The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.

References

Nov 27, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay Kalra
Apr 22, 2015·Clinical Therapeutics·Karen WhalenErin St Onge
May 6, 2015·Therapeutic Advances in Endocrinology and Metabolism·Aris LiakosApostolos Tsapas
Jul 8, 2015·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
May 22, 2016·Diabetes Care·Muhammad Abdul-GhaniRalph A DeFronzo
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Jun 25, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ginger CarlsSteven V Edelman
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Dec 22, 2017·Diabetes Care
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez

❮ Previous
Next ❯

Citations

Nov 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Mattia GalliNadia Aspromonte
Nov 18, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Anastasia Erythropoulou-KaltsidouKonstantinos Tziomalos
Jan 16, 2021·Clinical Medicine Insights. Endocrinology and Diabetes·Hannah Gardner, Osama Hamdy

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Expert Review of Clinical Pharmacology
Muralikrishna Gangadharan Komala, Amanda Mather
Expert Opinion on Pharmacotherapy
Vidhya Jahagirdar, Anthony H Barnett
Expert Opinion on Investigational Drugs
Angela N PaisleyHandrean Soran
© 2022 Meta ULC. All rights reserved